In 1985, the Nobel Prize in Physiology or Medicine was awarded to Michael Brown and Joseph Goldstein for identifying the receptor that clears LDL particles from the bloodstream. High blood levels of ...

National Institute of Health (NIH) scientists have made a significant breakthrough in understanding how "bad" cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body.

A peptide vaccine targeting PCSK9 has demonstrated sustained antibody responses and reductions in LDL cholesterol and atherosclerotic plaque formation in animal models, offering a potential long-term ...

Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. We conducted a randomized, ...

Low-density lipoprotein, known as LDL, is a complex structure with several components that allow cholesterol to circulate in the bloodstream, a watery environment. LDL is the primary mechanism used to ...

Despite decades of study, a pharmacopoeia of medicines, and untold millions in pharmaceutical research, heart disease remains the leading cause of death around the world. Excess cholesterol in ...

Low-density lipoproteins (LDL)—commonly known as bad cholesterol—have long been on scientists' radar as a major contributor to heart disease. But these microscopic troublemakers have hidden their ...

Michael D. Shapiro, DO, discusses how lipoproteins, chiefly LDL (low-density lipoprotein) and Lp(a) (lipoprotein a), drive atherosclerotic heart disease. This is a video synopsis/summary of an ...

Lipoprotein (a) is a low-density lipoprotein that transports cholesterol in the blood. The lipoprotein (a) test — or Lp(a) test — determines the level of this lipoprotein in the blood, and its results ...

National Institute of Health (NIH) scientists have made a significant breakthrough in understanding how "bad" cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body.